Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G, Tentori L, Navarra P.
Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Review.
Related citations
Chemopotentiation by PARP inhibitors in cancer therapy.
Tentori L, Graziani G.
Pharmacol Res. 2005 Jul;52(1):25-33. Review.
Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?
Pharmacol Res. 2007 May;55(5):359-69. Epub 2007 Feb 3. Review.
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
Tentori L, Portarena I, Graziani G.
Pharmacol Res. 2002 Feb;45(2):73-85. Review.
Recent approaches to improve the antitumor efficacy of temozolomide.
Curr Med Chem. 2009;16(2):245-57. Review.
The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
Tentori L, Dorio AS, Muzi A, Lacal PM, Ruffini F, Navarra P, Graziani G.
Oncol Rep. 2008 Apr;19(4):1039-43.
Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine.
Giuliani A, Tentori L, Pepponi R, Porcelli SA, Aquino A, Orlando L, Sugita M, Brenner MB, Bonmassar E, Graziani G.
Pharmacol Res. 1997 Feb;35(2):135-40.
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, Xu W, Kalish V, Zupi G, Zhang J, Graziani G.
Clin Cancer Res. 2003 Nov 1;9(14):5370-9.
The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
Tentori L, Dorio AS, Mazzon E, Muzi A, Sau A, Cuzzocrea S, Vernole P, Federici G, Caccuri AM, Graziani G.
Eur J Cancer. 2011 May;47(8):1219-30. doi: 10.1016/j.ejca.2010.12.008. Epub 2011 Jan 25.
Pharmacological strategies to increase the antitumor activity of methylating agents.
Curr Med Chem. 2002 Jul;9(13):1285-301. Review.
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity.
Tentori L, Muzi A, Dorio AS, Bultrini S, Mazzon E, Lacal PM, Shah GM, Zhang J, Navarra P, Nocentini G, Cuzzocrea S, Graziani G.
Eur J Cancer. 2008 Jun;44(9):1302-14. doi: 10.1016/j.ejca.2008.03.019. Epub 2008 Apr 24.
Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells.
Graziani G, Tentori L, Portarena I, Vergati M, Navarra P.
Endocrinology. 2003 Jul;144(7):2822-8.
Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Tentori L, Leonetti C, Scarsella M, Muzi A, Vergati M, Forini O, Lacal PM, Ruffini F, Gold B, Li W, Zhang J, Graziani G.
Eur J Cancer. 2005 Dec;41(18):2948-57. Epub 2005 Nov 8.
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Tentori L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, Forini O, Lapidus R, Xu W, Dorio AS, Zhang J, Cuzzocrea S, Graziani G.
FASEB J. 2006 Aug;20(10):1709-11. Epub 2006 Jun 29.
Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
Tentori L, Muzi A, Dorio AS, Scarsella M, Leonetti C, Shah GM, Xu W, Camaioni E, Gold B, Pellicciari R, Dantzer F, Zhang J, Graziani G.
Curr Cancer Drug Targets. 2010 Jun;10(4):368-83.
Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.
Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, Navarra P.
Mol Cell Endocrinol. 2007 Jan 29;264(1-2):44-9. Epub 2006 Nov 9.
Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes.
Tentori L, Portarena I, Vernole P, Gold B, Graziani G.
Cancer Chemother Pharmacol. 2002 Mar;49(3):217-24. Epub 2002 Jan 22.
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Tentori L, Portarena I, Barbarino M, Balduzzi A, Levati L, Vergati M, Biroccio A, Gold B, Lombardi ML, Graziani G.
Mol Pharmacol. 2003 Jan;63(1):192-202.
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.
Tentori L, Leonetti C, Scarsella M, d'Amati G, Portarena I, Zupi G, Bonmassar E, Graziani G.
Blood. 2002 Mar 15;99(6):2241-4.
Targeted therapy for brain tumours: role of PARP inhibitors.
Leonetti C, Biroccio A, Graziani G, Tentori L.
Curr Cancer Drug Targets. 2012 Mar;12(3):218-36. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on